ANRO241220P12500
- 8.45
- 0.000.00%
Alto Neuroscience Newsroom
Potential Catalysts and Strategic Focus: Analyzing Alto Neuroscience's Upcoming Trials and Precision Psychiatry Approach
Alto Neuroscience Strengthens Financial Position Amid Increased R&D
Alto Neuroscience Analyst Ratings
Stifel Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Cuts Target Price to $10
Express News | Alto Neuroscience Inc : Stifel Cuts Target Price to $10 From $32
TD Cowen Maintains Alto Neuroscience(ANRO.US) With Buy Rating
Alto Neuroscience Cash Position Also Expected to Fund at Least Four Additional Clinical Study Readouts >ANRO
Alto Neuroscience 3Q Loss/Shr 62c >ANRO
Alto Neuroscience Q3 2024 GAAP EPS $(0.62) Beats $(0.65) Estimate
Alto Neuroscience | 10-Q: Q3 2024 Earnings Report
Alto Neuroscience | 8-K: Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Express News | Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Press Release: Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Alto Neuroscience to Participate in Upcoming Investor Conferences
Notable Analyst Calls This Week: McDonald's, Apple and Enphase Energy Among Top Picks
Wedbush Downgrades Alto Neuroscience to Neutral Following ALTO-100 Readout
Alto Neuroscience ANRO Phase 2b Failed; Tevogen TVGN MSFT AI Deal
Top Midday Decliners
Trending Stocks Today | La Rosa Holdings Shoots up 196.1%
October 23rd - US stocks trending in regular trading hours.Gainers: $La Rosa Holdings(LRHC.US)$ surges 196.1% to $1.45 with a turnover of $209.25 million. $AgEagle Aerial Systems(UAVS.US)$ shoots up 8
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform